GlassScriptPhysician profile
Nancy L Folley
NPI 1154814119
$36,885.51
in general payments reported to CMS, 2019-2025
46 companies · $3,342 in 2025
The $3,342 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $8,640 · 2023: $6,015 · 2024: $6,175 · 2025: $3,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,822 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,344 · Education: $276 · Travel and Lodging: $89.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,822.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,343.75 |
| Education | $276.49 |
| Travel and Lodging | $89.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,769.50 | 2021-2025 | |
| Biogen, INC. | $1,991.16 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Allergan, INC. | $1,605.02 | 2021 | |
| Emd Serono, INC. | $1,355.76 | 2021-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $1,082.60 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $1,000.04 | 2021-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $772.06 | 2021-2025 | |
| Ucb, INC. | $748.88 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Lundbeck LLC | $730.27 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $648.78 | 2021-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $600.94 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $525.70 | 2021-2024 | Ultomiris, Soliris |
| Celgene Corporation | $490.70 | 2021-2025 | Zeposia |
| Pfizer INC. | $487.58 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $467.60 | 2023-2024 | Aptiom, Latuda |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $414.70 | 2021-2023 | Lyvispah, Rytary |
| Amgen INC. | $407.05 | 2021-2025 | Aimovig |
| Eisai INC. | $400.91 | 2021-2025 | |
| Lilly USA, LLC | $364.21 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Otsuka America Pharmaceutical, INC. | $359.92 | 2021-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $265.85 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $224.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $202.47 | 2021-2022 | |
| Neurelis, INC. | $200.33 | 2024-2025 | Valtoco |
| Argenx US, INC. | $186.72 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Mallinckrodt Hospital Products INC. | $179.07 | 2021-2022 | |
| Corium, LLC | $163.16 | 2022-2025 | Adlarity, Azstarys |
| Impel Pharmaceuticals INC. | $154.57 | 2023 | Trudhesa |
| Tg Therapeutics, INC. | $148.99 | 2023-2025 | |
| Avanir Pharmaceuticals, INC. | $120.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $103.24 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $84.44 | 2024 | Xeomin, Ampyra, Inbrija |
| Banner Life Sciences, LLC | $73.81 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $69.45 | 2022 | |
| Kyowa Kirin, INC. | $62.80 | 2024 | Nourianz |
| Jazz Pharmaceuticals INC. | $62.43 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $62.33 | 2024 | |
| Ani Pharmaceuticals, INC. | $52.75 | 2025 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $50.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $46.65 | 2025 | Wainua |
| Axsome Therapeutics, INC. | $40.82 | 2025 | Symbravo |
| Supernus Pharmaceuticals, INC. | $28.36 | 2021-2025 | Qelbree |
| Genentech USA, INC. | $24.39 | 2022 | |
| Mdd US Operations, LLC | $20.75 | 2023 | Gocovri |
| Novocure INC. | $17.32 | 2025 | Optune Gio |
| Livanova USA, INC. | $15.70 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Folley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.